Hikma Pharmaceuticals (HIK)

Sector:

Pharma and Biotech

Index:

FTSE 100

1,891.00p
   
  • Change Today:
      16.00p
  • 52 Week High: 2,205.00p
  • 52 Week Low: 1,722.00p
  • Currency: UK Pounds
  • Shares Issued: 221.89m
  • Volume: 414,106
  • Market Cap: £4,195.85m
  • RiskGrade: 125

Wednesday preview: WA votes in Parliament, Hikma Pharmaceuticals

By Alexander Bueso

Date: Tuesday 12 Mar 2019

LONDON (ShareCast) - (Sharecast News) - Investors may be facing heightened volatility on Wednesday, as financial markets digest the result of Parliament's vote on Theresa May's proposal for the UK's withdrawal agreement with the European Union.
Going into the vote, some analysts were putting the odds of a vote in her favour at roughly 10%, which would trigger a vote on a no-deal exit on Wednesday and if the result of that was negative, then a third vote on Thursday on asking Brussels for a short on extension on Article 50.

Hence, heightened uncertainty remained, among other reasons because the EU might impose conditions on any extension.

As well, there was the possibility of various wildcards to contend with, including May's resignation or a no-confidence vote.

Against that backdrop, the Chancellor was to deliver his Spring Statement, although the markets' focus may well turn out to be on the OBR's forecasts for economic growth over the next fiscal year, which might limit Philip Hammond's to dole out largesse.

On the corporate side of things, Hikma Pharmaceuticals is among the companies slated to release full-year results.

Consensus has penciled-in earnings per share of $1.29 versus $1.05 the last time around on a 6.7% increase in sales to $2.07bn, likely helped by better-than-expected sales of injectables Stateside and higher revenues from its generics arm.

But supply disruptions, especially in opioids, meant that management was likely to offer "cautious" guidance on US injectables heading into fiscal year 2019, which might trigger consensus downgrades, Numis analyst Paul Cordon said.

"We also note the weak recent Q4 performance from Teva and Mylan, which may affect the generics outlook into FY19," he added.

"We would not expect any further update on the generic Advair program at this point with the trial nearing completion and due to be submitted to the FDA around the middle of the year

Wednesday March 13

INTERNATIONAL ECONOMIC ANNOUNCEMENTS

Crude Oil Inventories (US) (14:30)

Industrial Production (EU) (10:00)

MBA Mortgage Applications (US) (11:00)

Producer Price Index (US) (12:30)

Q4

Transgloble Energy Corporation NPV (DI)

FINALS

Advanced Medical Solutions Group, Avast, Balfour Beatty, Burford Capital , Dignity, ECSC Group, EKF Diagnostics Holdings , Empresaria Group, Gem Diamonds Ltd. (DI), Hikma Pharmaceuticals, Kenmare Resources, Lookers, Manx Telecom , Marshall Motor Holdings, Morrison (Wm) Supermarkets, Prudential, Quilter, SafeCharge International Group Limited (DI), Sigmaroc , Standard Life Aberdeen, StatPro Group, Transgloble Energy Corporation NPV (DI)

AGMS

Independent Inv Trust







Email this article to a friend

or share it with one of these popular networks:


Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: RiskGrade figures are provided by RiskMetrics.

 

HIK Market Data

Currency UK Pounds
Share Price 1,891.00p
Change Today 16.00p
% Change 0.85 %
52 Week High 2,205.00p
52 Week Low 1,722.00p
Volume 414,106
Shares Issued 221.89m
Market Cap £4,195.85m
RiskGrade 125

HIK Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
48.07% below the market average48.07% below the market average48.07% below the market average48.07% below the market average48.07% below the market average
1.96% above the sector average1.96% above the sector average1.96% above the sector average1.96% above the sector average1.96% above the sector average
Price Trend
44.88% above the market average44.88% above the market average44.88% above the market average44.88% above the market average44.88% above the market average
69.81% above the sector average69.81% above the sector average69.81% above the sector average69.81% above the sector average69.81% above the sector average
Income
11.05% above the market average11.05% above the market average11.05% above the market average11.05% above the market average11.05% above the market average
71.43% above the sector average71.43% above the sector average71.43% above the sector average71.43% above the sector average71.43% above the sector average
Growth
31.5% below the market average31.5% below the market average31.5% below the market average31.5% below the market average31.5% below the market average
39.39% below the sector average39.39% below the sector average39.39% below the sector average39.39% below the sector average39.39% below the sector average

What The Brokers Say

Strong Buy 4
Buy 2
Neutral 4
Sell 1
Strong Sell 0
Total 11
buy
Broker recommendations should not be taken as investment advice, and are provided by the authorised brokers listed on this page.

HIK Dividends

  Latest Previous
  Final Interim
Ex-Div 21-Mar-24 10-Aug-23
Paid 03-May-24 15-Sep-23
Amount 47.00¢ 25.00¢

Trades for 28-Jun-2024

Time Volume / Share Price
16:37 2,829 @ 1,891.00p
16:35 2,539 @ 1,891.00p
16:35 294 @ 1,891.00p
16:35 273,431 @ 1,891.00p
16:35 300 @ 1,891.00p

HIK Key Personnel

CEO Riad Mishlawi

Top of Page